Design of the FIBRONEER-SARD trial: a phase IIIb randomised placebo-controlled trial of nerandomilast in patients with autoimmune interstitial lung disease

Objectives The FIBRONEER-SARD trial (NCT06806592) is investigating the efficacy, safety, and tolerability of nerandomilast in patients with fibrosing autoimmune interstitial lung diseases (ILDs) who are receiving immunomodulatory therapies and are not required to have progressive disease at enrolment. Methods Participants have rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissue disease. At enrolment, participants must have fibrotic ILD of >10% extent on high-resolution computed tomography, have shown no absolute improvement in forced vital capacity (FVC) % predicted >5% in the last 15 months, and have taken stable immunomodulatory therapy for ≥6 months (≥3 months for IIM). Patients will be randomised 1:1 to receive nerandomilast 18 mg twice a day or placebo, stratified by number of immunomodulatory therapies (1 vs >1) and by presence/absence of progressive pulmonary fibrosis. Results The primary endpoint is the absolute change from baseline in quantitative ILD score (%) at week 26. Patients will continue to receive randomised therapy until the last patient completes the week 26 visit, but for ≤52 weeks. Secondary endpoints include absolute changes in quantitative lung fibrosis and ground-glass opacity scores (%) and FVC (mL) at week 26, and occurrence of infection-related adverse events over the whole trial. Further endpoints include patient-reported outcomes and measures of disease activity specific to the underlying autoimmune disease. Conclusions The FIBRONEER-SARD trial will provide insights into the efficacy, safety, and tolerability of nerandomilast in patients with fibrosing autoimmune ILDs with and without progressive disease, who are taking a broad range of immunomodulatory therapies.

Authors

Institutions

Publication Details

Journal
EULAR Rheumatology Open
Published
2026-11-21
DOI
https://doi.org/10.1016/j.ero.2026.100277
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Design of the FIBRONEER-SARD trial: a phase IIIb randomised placebo-controlled trial of nerandomilast in patients with autoimmune interstitial lung disease

Anna‐Maria Hoffmann‐Vold, Sara Tomassetti, Elisabetta Augusta Renzoni, Helmut Prosch et al.
EULAR Rheumatology Open
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Design of the FIBRONEER-SARD trial: a phase IIIb randomised placebo-controlled trial of nerandomilast in patients with autoimmune interstitial lung disease

Anna‐Maria Hoffmann‐Vold, Sara Tomassetti, Elisabetta Augusta Renzoni, Helmut Prosch, Elizabeth R. Volkmann, Rohit Aggarwal, Jeffrey A. Sparks, Shervin Assassi, Steven Sambevski, Peide Li, Frank Risse, Francesco Bonella, Klaus B. Rohr, Madhu Kanakapura, Masataka Kuwana, Oliver Distler
article en

Abstract

Objectives The FIBRONEER-SARD trial (NCT06806592) is investigating the efficacy, safety, and tolerability of nerandomilast in patients with fibrosing autoimmune interstitial lung diseases (ILDs) who are receiving immunomodulatory therapies and are not required to have progressive disease at enrolment. Methods Participants have rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissue disease. At enrolment, participants must have fibrotic ILD of >10% extent on high-resolution computed tomography, have shown no absolute improvement in forced vital capacity (FVC) % predicted >5% in the last 15 months, and have taken stable immunomodulatory therapy for ≥6 months (≥3 months for IIM). Patients will be randomised 1:1 to receive nerandomilast 18 mg twice a day or placebo, stratified by number of immunomodulatory therapies (1 vs >1) and by presence/absence of progressive pulmonary fibrosis. Results The primary endpoint is the absolute change from baseline in quantitative ILD score (%) at week 26. Patients will continue to receive randomised therapy until the last patient completes the week 26 visit, but for ≤52 weeks. Secondary endpoints include absolute changes in quantitative lung fibrosis and ground-glass opacity scores (%) and FVC (mL) at week 26, and occurrence of infection-related adverse events over the whole trial. Further endpoints include patient-reported outcomes and measures of disease activity specific to the underlying autoimmune disease. Conclusions The FIBRONEER-SARD trial will provide insights into the efficacy, safety, and tolerability of nerandomilast in patients with fibrosing autoimmune ILDs with and without progressive disease, who are taking a broad range of immunomodulatory therapies.

EULAR Rheumatology OpenVol. 2(4)
National Health Service (GB), Oslo University Hospital (NO), Brigham and Women's Hospital (US), Boehringer Ingelheim (Germany) (DE), Harvard University (US), University of California, Los Angeles (US), University of Pittsburgh (US), Guy's and St Thomas' NHS Foundation Trust (GB), University of Zurich (CH), Ruhrlandklinik (DE), Royal Brompton Hospital (GB), University Hospital of Zurich (CH), Azienda Ospedaliero-Universitaria Careggi (IT), Essen University Hospital (DE), Boehringer Ingelheim (United States) (US), University of Florence (IT), Medical University of Vienna (AT), Nippon Medical School (JP), The University of Texas Health Science Center at Houston (US)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon